20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
TP1807 | EGF Receptor Substrate 2 Phospho-Tyr5 | ||
EGF Receptor Substrate 2 (Phospho-Tyr5) is a biologically active peptide derived from an autophosphorylation site (Tyr992) of EGFR. | |||
T3506 | Nazartinib | EGF816,NVS-816 | EGFR |
Nazartinib (EGF816) (EGF816, NVS-816) is a covalent, irreversible, mutant-selective EGFR inhibitor that has nanomolar inhibitory potency against activating mt (L858R, ex19del) and T790M mt, with up to 60-fold selectivity... | |||
T75764 | EGF Receptor Substrate 2 (Phospho-Tyr5) | ||
EGF Receptor Substrate 2 (Phospho-Tyr5) is a biologically active peptide derived from an autophosphorylation site (Tyr 992 ) of epidermal growth factor receptor (EGFR). | |||
T76472 | EGF-R (661-681) T669 Peptide | ||
EGF-R (661-681) T669 Peptide, a MAPK substrate, facilitates the measurement of MAPK catalytic activity [1]. | |||
T14004 | 1A-116 | Rho | |
1A-116 is a specific inhibitor of Rac1 . | |||
T8574 | SPHINX | Others | |
SPHINX is a new generation inhibitor of SPRK1 | |||
T11156L | Nazartinib mesylate | EGF816 (mesylate) | Others |
Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant). | |||
T9927 | Panitumumab | EGFR | |
Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR). | |||
T11156 | Nazartinib S-enantiomer | EGF816 (S-enantiomer) | Others |
Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib. | |||
T75120 | EGFR-IN-76 | EGFR | |
EGFR-IN-76 is a potent EGFR inhibitor. | |||
T37078 | VEGFR-2-IN-6 | VEGFR | |
VEGFR-2-IN-6 (WO 02/059110, example 64) is a potent inhibitor of VEGFR2, a crucial receptor involved in the regulation of angiogenesis [1]. | |||
T63732 | EGFR-IN-3 | Apoptosis , EGFR | |
EGFR-IN-3 is an EGFR inhibitor with potential antitumour activity.EGFR-IN-3 inhibits EGFRwt-TK and induces apoptosis (cell death), which can cause cells to block in the G2/M phase. | |||
T10802 | CHMFL-EGFR-202 | EGFR | |
CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases). | |||
T72924 | VEGFR-3-IN-1 | VEGFR | |
VEGFR-3-IN-1 is a novel potent and selective VEGFR3 inhibitor with an IC50 of 110.4 nM.VEGFR-3-IN-1 possesses antitumor activity, inactivates the VEGFR3 signaling pathway, and inhibits the proliferation and migration of ... | |||
T11161 | EGFR-IN-7 | TQB3804 | EGFR |
EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor. | |||
T11160 | EGFR-IN-5 | EGFR | |
EGFR-IN-5 is a selective inhibitor of EGFR. The IC50s for EGFR, EGFR(L858R), EGFR(L858R/T790M), and EGFR(L858R/T790M/C797S) are 10.4, 1.1, 34, 7.2 nM, respectively. | |||
T9979 | VEGFR-2-IN-29 | VEGFR | |
VEGFR-2-IN-29 is a VEGFR2 inhibitor. | |||
T16162 | Mutated EGFR-IN-1 | Osimertinib analog | EGFR |
Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant. | |||
T10123 | VEGFR-2-IN-9 | KDR-in-4 | VEGFR |
VEGFR-2-IN-9 (KDR-in-4) is a potent KDR/VEGFR2 inhibitor (IC50: 7 nM). It can be used to study breast cancer. | |||
T11157L | EGFR-IN-1 hydrochloride | EGFR | |
EGFR-IN-1 hydrochloride is an irreversible and specific inhibitor of L858R/T790M mutant EGFR with 100-fold selectivity over wild-type EGFR. EGFR-IN-1 hydrochloride exhibits potent antitumor and antiproliferative activity... |